Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis.

[1]  L. Køber,et al.  Stroke in Patients With Aortic Stenosis: The Simvastatin and Ezetimibe in Aortic Stenosis Study , 2014, Stroke.

[2]  C. Hassager,et al.  Short-term hemodynamic effect of angiotensin-converting enzyme inhibition in patients with severe aortic stenosis: a placebo-controlled, randomized study. , 2014, American heart journal.

[3]  R. Nishimura,et al.  Systemic Hypertension in Low-Gradient Severe Aortic Stenosis With Preserved Ejection Fraction , 2013, Circulation.

[4]  B. Prendergast,et al.  A prospective, double-blinded, randomized trial of Ramipril in asymptomatic aortic stenosis: the RIAS trial , 2013 .

[5]  Francis G Spinale,et al.  Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. , 2012, The Journal of thoracic and cardiovascular surgery.

[6]  C. Lang,et al.  Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. , 2011, Journal of the American College of Cardiology.

[7]  J. Després,et al.  Oxidized low-density lipoprotein, angiotensin II and increased waist cirumference are associated with valve inflammation in prehypertensive patients with aortic stenosis. , 2010, International journal of cardiology.

[8]  E. Staal,et al.  Impact of hypertension on left ventricular structure in patients with asymptomatic aortic valve stenosis (a SEAS substudy) , 2010, Journal of hypertension.

[9]  J. Chambers,et al.  Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. , 2008, The New England journal of medicine.

[10]  B. Carabello.  What is new in the 2006 ACC/AHA guidelines on valvular heart disease? , 2008, Current cardiology reports.

[11]  I. Holme,et al.  Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. , 2007, The American journal of cardiology.

[12]  J. Filipovský,et al.  Severe aortic stenosis and its association with hypertension: Analysis of clinical and echocardiographic parameters , 2007, Blood pressure.

[13]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[14]  J. Bermejo,et al.  Effects of angiotensin converting enzyme inhibitors in hypertensive patients with aortic valve stenosis: a drug withdrawal study , 2005, Heart.

[15]  V. Dzau.  The cardiovascular continuum and renin–angiotensin–aldosterone system blockade , 2005, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[16]  M. Schemper,et al.  Statins but Not Angiotensin-Converting Enzyme Inhibitors Delay Progression of Aortic Stenosis , 2004, Circulation.

[17]  C. Otto,et al.  Hemodynamic Effects of the Angiotensin-Converting Enzyme Inhibitor, Ramipril, in Patients with Mild to Moderate Aortic Stenosis and Preserved Left Ventricular Function , 2004, Journal of Investigative Medicine.

[18]  R Alagesan,et al.  Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). , 2004, American heart journal.

[19]  M. Schemper,et al.  Mild and moderate aortic stenosis. Natural history and risk stratification by echocardiography. , 2003, European heart journal.

[20]  P. Faggiano,et al.  Symptomatic Aortic Stenosis: Does Systemic Hypertension Play an Additional Role? , 2003, Hypertension.

[21]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[22]  C. Otto,et al.  Association of Angiotensin-Converting Enzyme With Low-Density Lipoprotein in Aortic Valvular Lesions and in Human Plasma , 2002, Circulation.

[23]  E Fleck,et al.  Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. , 2001, Journal of the American College of Cardiology.

[24]  Bonnie K. Lind,et al.  Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. , 1999, The New England journal of medicine.

[25]  R. D'Agostino.  Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .

[26]  G. Mulley,et al.  Why deny ACE inhibitors to patients with aortic stenosis? , 1998, The Lancet.

[27]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[28]  J. Chambers,et al.  Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. , 2009, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[29]  S. Chrysant.  Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum. , 2008, Clinical therapeutics.